While an Omicron-specific booster of Moderna’s Covid-19 vaccine probably won’t be ready in the next couple of months, according to a Reuters report, CEO Stéphane Bancel says another shot will likely…
ALS drug developer Amylyx got off its IPO on Friday, raising $190 million after pricing its stock at the midrange of the offering and bumping up the offering by 1.2 million shares. Coming out at $19 a…
Cytokinetics stumbled a bit with its closely watched lead heart drug over the last year or so, losing two pharma partners after missing a key secondary endpoint in a Phase III study. But things are…
In the year-plus since Roger Perlmutter left his post leading Merck’s R&D efforts, the Big Pharma’s new leadership has continued to pursue an aggressive dealmaking strategy. On Friday, Merck enlisted…
AstraZeneca — or, more specifically, its rare disease subsidiary Alexion — is serious about getting into ATTR amyloidosis. Just weeks after licensing a late-stage antisense candidate from Ionis,…
After starting up with a $12 million Series A in 2019, California outfit AN2 Therapeutics issued its first press release in over 2 years — and its second ever: The ultra-quiet biotech has raised an…
Atea Pharmaceuticals is still determined to get its COVID-19 antiviral through clinical trials, but without a partner to collaborate with, the biotech is also raiding Merck’s storeroom to make a play…
After offloading China rights to a heart failure drug, Cytokinetics has found a partner in Royalty Pharma for the rest of the world. Royalty will pay up to $450 million for the chance to support the…
Days after landing a partial guilty verdict in disgraced Theranos CEO Elizabeth Holmes’ federal fraud trial, the U.S. Department of Justice’s crusade against healthcare scammers rages on.
Merck is taking a deep dive into complex proteins with the help of AI-powered drug discovery company Absci. The two companies have signed a research collaboration for up to three targets in a deal…
